MedPath

Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage

Phase 3
Completed
Conditions
Recurrent Miscarriage
Interventions
Registration Number
NCT00193674
Lead Sponsor
Abbott Products
Brief Summary

The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with dydrogesterone (Duphaston).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
71
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2Placebo-
1Dydrogesterone-
Primary Outcome Measures
NameTimeMethod
Cytokine ratio IFN/IL-1014 weeks treatment after diagnosed pregnancy (week of gestation 4 to 18)
Secondary Outcome Measures
NameTimeMethod
Exploratory analysis of pregnancy outcome by monitoring biochemical and clinical pregnancy parameters, weekly evaluation of serum progesteroneFirst trimester of pregnancy

Trial Locations

Locations (3)

Site Reference ID/Investigator# 61183

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 61184

🇵🇱

Szczecin, Poland

Site Reference ID/Investigator# 61182

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath